Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Imatinib Drug Market by Application (Aggressive Systemic Mastocytosis (ASM), Chronic Eosinophilic Leukemia (CEL), Dermatofibrosarcoma Protuberans (DFSP), Gastrointestinal Stromal Tumors (GIST), Hyper-eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Philadelphia Chromosome-positive Acute, Lymphoblastic Leukemia (Ph+ ALL), Philadelphia Chromosome-positive Chronic Myeloid, Leukemia (Ph+ CML)) and by Drug Formulation (Tablets, Capsules): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02316

Pages: NA

Charts: NA

Tables: NA

Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the imatinib drug market. According to the National Cancer Institute, in June 2017, it was estimated that there will be around 62,130 and 24,500 people with new cases and death due to leukemia, respectively, in the U.S.

Furthermore, rise in healthcare expenditure and increase in awareness of cancer by government and private organizations are anticipated to boost the market growth. In addition, R&D activities related to imatinib are anticipated to present new opportunities during the forecast period. However, high cost of imatinib; adverse effects; presence of substitutes, such as sprycel, tarceva, and tasigna; and stringent government regulations may hinder the market growth.

The imatinib drug market is segmented on the basis of application, drug formulation, and geography. Based on application, it is divided into aggressive systemic mastocytosis (ASM), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST), hyper-eosinophilic syndrome (HES), myelodysplastic syndrome (MDS), myeloproliferative diseases (MPD), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Based on the drug formulation, the market is bifurcated into tablets and capsules. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global imatinib drug market, with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report presents a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.

 Key Market Segments

  • By Application
    • Aggressive Systemic Mastocytosis (ASM)
    • Chronic Eosinophilic Leukemia (CEL)
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Gastrointestinal Stromal Tumors (GIST)
    • Hyper-eosinophilic Syndrome (HES)
    • Myelodysplastic Syndrome (MDS)
    • Myeloproliferative Diseases (MPD)
    • Philadelphia Chromosome-positive Acute
    • Lymphoblastic Leukemia (Ph+ ALL)
    • Philadelphia Chromosome-positive Chronic Myeloid
    • Leukemia (Ph+ CML)
  • By Drug Formulation
    • Tablets
    • Capsules
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Actavis Generics
  • Mylan Pharms Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories
  • Apotex Inc.
  • Novartis
  • Cipla Inc.
  • Sun Pharmaceuticals
  • Sanofi S.A.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: IMATINIB DRUG MARKET, BY APPLICATION

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Application

    • 4.2. Aggressive Systemic Mastocytosis (ASM)

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Chronic Eosinophilic Leukemia (CEL)

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Dermatofibrosarcoma Protuberans (DFSP)

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Gastrointestinal Stromal Tumors (GIST)

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Hyper-eosinophilic Syndrome (HES)

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Myelodysplastic Syndrome (MDS)

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Myeloproliferative Diseases (MPD)

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

    • 4.9. Philadelphia Chromosome-positive Acute

      • 4.9.1. Key Market Trends, Growth Factors and Opportunities

      • 4.9.2. Market Size and Forecast, By Region

      • 4.9.3. Market Share Analysis, By Country

    • 4.10. Lymphoblastic Leukemia (Ph+ ALL)

      • 4.10.1. Key Market Trends, Growth Factors and Opportunities

      • 4.10.2. Market Size and Forecast, By Region

      • 4.10.3. Market Share Analysis, By Country

    • 4.11. Philadelphia Chromosome-positive Chronic Myeloid

      • 4.11.1. Key Market Trends, Growth Factors and Opportunities

      • 4.11.2. Market Size and Forecast, By Region

      • 4.11.3. Market Share Analysis, By Country

    • 4.12. Leukemia (Ph+ CML)

      • 4.12.1. Key Market Trends, Growth Factors and Opportunities

      • 4.12.2. Market Size and Forecast, By Region

      • 4.12.3. Market Share Analysis, By Country

  • CHAPTER 5: IMATINIB DRUG MARKET, BY DRUG FORMULATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Formulation

    • 5.2. Tablets

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Capsules

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: IMATINIB DRUG MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Application

      • 6.2.3. Market Size and Forecast, By Drug Formulation

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Imatinib Drug Market

        • 6.2.5.1. Market Size and Forecast, By Application
        • 6.2.5.2. Market Size and Forecast, By Drug Formulation

      • 6.2.6. Canada Imatinib Drug Market

        • 6.2.6.1. Market Size and Forecast, By Application
        • 6.2.6.2. Market Size and Forecast, By Drug Formulation

      • 6.2.7. Mexico Imatinib Drug Market

        • 6.2.7.1. Market Size and Forecast, By Application
        • 6.2.7.2. Market Size and Forecast, By Drug Formulation

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Application

      • 6.3.3. Market Size and Forecast, By Drug Formulation

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Imatinib Drug Market

        • 6.3.5.1. Market Size and Forecast, By Application
        • 6.3.5.2. Market Size and Forecast, By Drug Formulation

      • 6.3.6. Germany Imatinib Drug Market

        • 6.3.6.1. Market Size and Forecast, By Application
        • 6.3.6.2. Market Size and Forecast, By Drug Formulation

      • 6.3.7. Italy Imatinib Drug Market

        • 6.3.7.1. Market Size and Forecast, By Application
        • 6.3.7.2. Market Size and Forecast, By Drug Formulation

      • 6.3.8. Spain Imatinib Drug Market

        • 6.3.8.1. Market Size and Forecast, By Application
        • 6.3.8.2. Market Size and Forecast, By Drug Formulation

      • 6.3.9. UK Imatinib Drug Market

        • 6.3.9.1. Market Size and Forecast, By Application
        • 6.3.9.2. Market Size and Forecast, By Drug Formulation

      • 6.3.10. Russia Imatinib Drug Market

        • 6.3.10.1. Market Size and Forecast, By Application
        • 6.3.10.2. Market Size and Forecast, By Drug Formulation

      • 6.3.11. Rest Of Europe Imatinib Drug Market

        • 6.3.11.1. Market Size and Forecast, By Application
        • 6.3.11.2. Market Size and Forecast, By Drug Formulation

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Application

      • 6.4.3. Market Size and Forecast, By Drug Formulation

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Imatinib Drug Market

        • 6.4.5.1. Market Size and Forecast, By Application
        • 6.4.5.2. Market Size and Forecast, By Drug Formulation

      • 6.4.6. Japan Imatinib Drug Market

        • 6.4.6.1. Market Size and Forecast, By Application
        • 6.4.6.2. Market Size and Forecast, By Drug Formulation

      • 6.4.7. India Imatinib Drug Market

        • 6.4.7.1. Market Size and Forecast, By Application
        • 6.4.7.2. Market Size and Forecast, By Drug Formulation

      • 6.4.8. South Korea Imatinib Drug Market

        • 6.4.8.1. Market Size and Forecast, By Application
        • 6.4.8.2. Market Size and Forecast, By Drug Formulation

      • 6.4.9. Australia Imatinib Drug Market

        • 6.4.9.1. Market Size and Forecast, By Application
        • 6.4.9.2. Market Size and Forecast, By Drug Formulation

      • 6.4.10. Thailand Imatinib Drug Market

        • 6.4.10.1. Market Size and Forecast, By Application
        • 6.4.10.2. Market Size and Forecast, By Drug Formulation

      • 6.4.11. Malaysia Imatinib Drug Market

        • 6.4.11.1. Market Size and Forecast, By Application
        • 6.4.11.2. Market Size and Forecast, By Drug Formulation

      • 6.4.12. Indonesia Imatinib Drug Market

        • 6.4.12.1. Market Size and Forecast, By Application
        • 6.4.12.2. Market Size and Forecast, By Drug Formulation

      • 6.4.13. Rest of Asia Pacific Imatinib Drug Market

        • 6.4.13.1. Market Size and Forecast, By Application
        • 6.4.13.2. Market Size and Forecast, By Drug Formulation

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Application

      • 6.5.3. Market Size and Forecast, By Drug Formulation

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Imatinib Drug Market

        • 6.5.5.1. Market Size and Forecast, By Application
        • 6.5.5.2. Market Size and Forecast, By Drug Formulation

      • 6.5.6. South Africa Imatinib Drug Market

        • 6.5.6.1. Market Size and Forecast, By Application
        • 6.5.6.2. Market Size and Forecast, By Drug Formulation

      • 6.5.7. Saudi Arabia Imatinib Drug Market

        • 6.5.7.1. Market Size and Forecast, By Application
        • 6.5.7.2. Market Size and Forecast, By Drug Formulation

      • 6.5.8. UAE Imatinib Drug Market

        • 6.5.8.1. Market Size and Forecast, By Application
        • 6.5.8.2. Market Size and Forecast, By Drug Formulation

      • 6.5.9. Argentina Imatinib Drug Market

        • 6.5.9.1. Market Size and Forecast, By Application
        • 6.5.9.2. Market Size and Forecast, By Drug Formulation

      • 6.5.10. Rest of LAMEA Imatinib Drug Market

        • 6.5.10.1. Market Size and Forecast, By Application
        • 6.5.10.2. Market Size and Forecast, By Drug Formulation

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novartis

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Glenmark Pharmaceuticals Ltd.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Sun Pharmaceuticals

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Actavis Generics

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Dr. Reddy's Laboratories

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Teva Pharmaceutical Industries Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Sanofi S.A.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Cipla Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Apotex Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Mylan Pharms Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL IMATINIB DRUG MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL IMATINIB DRUG MARKET FOR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL IMATINIB DRUG MARKET FOR CHRONIC EOSINOPHILIC LEUKEMIA (CEL), BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL IMATINIB DRUG MARKET FOR DERMATOFIBROSARCOMA PROTUBERANS (DFSP), BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL IMATINIB DRUG MARKET FOR GASTROINTESTINAL STROMAL TUMORS (GIST), BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL IMATINIB DRUG MARKET FOR HYPER-EOSINOPHILIC SYNDROME (HES), BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL IMATINIB DRUG MARKET FOR MYELODYSPLASTIC SYNDROME (MDS), BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL IMATINIB DRUG MARKET FOR MYELOPROLIFERATIVE DISEASES (MPD), BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL IMATINIB DRUG MARKET FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL IMATINIB DRUG MARKET FOR LYMPHOBLASTIC LEUKEMIA (PH+ ALL), BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL IMATINIB DRUG MARKET FOR PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL IMATINIB DRUG MARKET FOR LEUKEMIA (PH+ CML), BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL IMATINIB DRUG MARKET, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL IMATINIB DRUG MARKET FOR TABLETS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL IMATINIB DRUG MARKET FOR CAPSULES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL IMATINIB DRUG MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA IMATINIB DRUG, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 19. NORTH AMERICA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 20. U.S. IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 21. U.S. IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 22. CANADA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 23. CANADA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 24. MEXICO IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE IMATINIB DRUG, BY REGION, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 29. FRANCE IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. FRANCE IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 31. GERMANY IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 32. GERMANY IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 33. ITALY IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. ITALY IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 35. SPAIN IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 36. SPAIN IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 37. UK IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. UK IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 39. RUSSIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 40. RUSSIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 41. REST OF EUROPE IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 42. REST OF EUROPE IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 43. ASIA-PACIFIC IMATINIB DRUG, BY REGION, 2025-2033 ($MILLION)
  • TABLE 44. ASIA-PACIFIC IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 45. ASIA-PACIFIC IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 46. CHINA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. CHINA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 48. JAPAN IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 49. JAPAN IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 50. INDIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. INDIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 52. SOUTH KOREA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 53. SOUTH KOREA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 54. AUSTRALIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. AUSTRALIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 56. THAILAND IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 57. THAILAND IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 58. MALAYSIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. MALAYSIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 60. INDONESIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 61. INDONESIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 62. REST OF ASIA PACIFIC IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. REST OF ASIA PACIFIC IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 64. LAMEA IMATINIB DRUG, BY REGION, 2025-2033 ($MILLION)
  • TABLE 65. LAMEA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 66. LAMEA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 67. BRAZIL IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. BRAZIL IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 69. SOUTH AFRICA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 70. SOUTH AFRICA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 71. SAUDI ARABIA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. SAUDI ARABIA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 73. UAE IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 74. UAE IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 75. ARGENTINA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. ARGENTINA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 77. REST OF LAMEA IMATINIB DRUG, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 78. REST OF LAMEA IMATINIB DRUG, BY DRUG FORMULATION, 2025-2033 ($MILLION)
  • TABLE 79. NOVARTIS: KEY EXECUTIVES
  • TABLE 80. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 81. NOVARTIS: OPERATING SEGMENTS
  • TABLE 82. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 83. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. GLENMARK PHARMACEUTICALS LTD.: KEY EXECUTIVES
  • TABLE 85. GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • TABLE 86. GLENMARK PHARMACEUTICALS LTD.: OPERATING SEGMENTS
  • TABLE 87. GLENMARK PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 88. GLENMARK PHARMACEUTICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. SUN PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 90. SUN PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 91. SUN PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 92. SUN PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 93. SUN PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. ACTAVIS GENERICS: KEY EXECUTIVES
  • TABLE 95. ACTAVIS GENERICS: COMPANY SNAPSHOT
  • TABLE 96. ACTAVIS GENERICS: OPERATING SEGMENTS
  • TABLE 97. ACTAVIS GENERICS: PRODUCT PORTFOLIO
  • TABLE 98. ACTAVIS GENERICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. DR. REDDY'S LABORATORIES: KEY EXECUTIVES
  • TABLE 100. DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • TABLE 101. DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
  • TABLE 102. DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 103. DR. REDDY'S LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 110. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 111. SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 112. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 113. SANOFI S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. CIPLA INC.: KEY EXECUTIVES
  • TABLE 115. CIPLA INC.: COMPANY SNAPSHOT
  • TABLE 116. CIPLA INC.: OPERATING SEGMENTS
  • TABLE 117. CIPLA INC.: PRODUCT PORTFOLIO
  • TABLE 118. CIPLA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. APOTEX INC.: KEY EXECUTIVES
  • TABLE 120. APOTEX INC.: COMPANY SNAPSHOT
  • TABLE 121. APOTEX INC.: OPERATING SEGMENTS
  • TABLE 122. APOTEX INC.: PRODUCT PORTFOLIO
  • TABLE 123. APOTEX INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. MYLAN PHARMS INC.: KEY EXECUTIVES
  • TABLE 125. MYLAN PHARMS INC.: COMPANY SNAPSHOT
  • TABLE 126. MYLAN PHARMS INC.: OPERATING SEGMENTS
  • TABLE 127. MYLAN PHARMS INC.: PRODUCT PORTFOLIO
  • TABLE 128. MYLAN PHARMS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL IMATINIB DRUG MARKET SEGMENTATION
  • FIGURE 2. GLOBAL IMATINIB DRUG MARKET
  • FIGURE 3. SEGMENTATION IMATINIB DRUG MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN IMATINIB DRUG MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALIMATINIB DRUG MARKET
  • FIGURE 11. IMATINIB DRUG MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 12. IMATINIB DRUG MARKET FOR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. IMATINIB DRUG MARKET FOR CHRONIC EOSINOPHILIC LEUKEMIA (CEL), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. IMATINIB DRUG MARKET FOR DERMATOFIBROSARCOMA PROTUBERANS (DFSP), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. IMATINIB DRUG MARKET FOR GASTROINTESTINAL STROMAL TUMORS (GIST), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. IMATINIB DRUG MARKET FOR HYPER-EOSINOPHILIC SYNDROME (HES), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. IMATINIB DRUG MARKET FOR MYELODYSPLASTIC SYNDROME (MDS), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. IMATINIB DRUG MARKET FOR MYELOPROLIFERATIVE DISEASES (MPD), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. IMATINIB DRUG MARKET FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. IMATINIB DRUG MARKET FOR LYMPHOBLASTIC LEUKEMIA (PH+ ALL), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. IMATINIB DRUG MARKET FOR PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. IMATINIB DRUG MARKET FOR LEUKEMIA (PH+ CML), BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. IMATINIB DRUG MARKET SEGMENTATION, BY BY DRUG FORMULATION
  • FIGURE 24. IMATINIB DRUG MARKET FOR TABLETS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. IMATINIB DRUG MARKET FOR CAPSULES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 27. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 28. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 29. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 30. COMPETITIVE DASHBOARD
  • FIGURE 31. COMPETITIVE HEATMAP: IMATINIB DRUG MARKET
  • FIGURE 32. TOP PLAYER POSITIONING, 2024
  • FIGURE 33. NOVARTIS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. NOVARTIS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. NOVARTIS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. GLENMARK PHARMACEUTICALS LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. GLENMARK PHARMACEUTICALS LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. GLENMARK PHARMACEUTICALS LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. SUN PHARMACEUTICALS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. SUN PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. SUN PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. ACTAVIS GENERICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. ACTAVIS GENERICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. ACTAVIS GENERICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. DR. REDDY'S LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. DR. REDDY'S LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. DR. REDDY'S LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. SANOFI S.A.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. SANOFI S.A.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. SANOFI S.A.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. CIPLA INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. CIPLA INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. CIPLA INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. APOTEX INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. APOTEX INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. APOTEX INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. MYLAN PHARMS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. MYLAN PHARMS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. MYLAN PHARMS INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Imatinib Drug Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved